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Background
New scientific progress in the “precision medicines”
direction and a better diagnosis of rare diseases have led
Regulators and Payers to focus their vigilance towards
the real life setting. Although Regulators and Payers are
taking into consideration patient pressures for rapid
access to treatment, nevertheless they must balance the
difficulties of taking significant decision coping with
uncertainties when deciding on pricing and reimburse-
ment processes.
Materials and methods
A large number of mechanisms (Managed Entry Agree-
ments) have been developed to limit the reimbursement of
medicines to those subpopulations that are most likely to
benefit from treatment. MEA are playing a key role in
bridging the possible gap by the management of uncer-
tainty in knowledge relating to pricing and reimbursement
of new medicines.
Furthermore, monitoring registries represent one of the
most advanced experience through all developed MEA
tools. The aim of these registers is to define patient elig-
ibility to a treatment by ensuring the proper use of the
medicinal product according to the approved indications
and concerning decision taken on reimbursement.
According to the variety of mechanisms and the way
they are structured, MEAs offer a wide flexibility able to
deal with different types of uncertainties at the same time
through the monitoring and combination of financial and
performance-based agreements (e.g. budget impact, weak-
ness in clinical evidence, etc).
A taxonomy has been developed within the European
project “Capacity building on managed entry agreements
for innovative medicines” in order to enable the provision
of a solid guide in the process of identifying the most
appropriate scheme to be adopted in each specific situation.
Regarding the objective of the MoCA project to iden-
tify the pathway, that may facilitate the access of OMP
to the market, it was very hard to find agreements
among all participants on how to facilitate the access of
orphan drugs in the real life setting, given the high cost
and the lack of evidence of these products.
Results
Hence the use of MEAs representing a significant tool for
the management of a sustainable pharmaceutical expendi-
ture and also for the generation of further clinical evi-
dences by registries’ adoption, they can be considered the
key element to overcome this concern.
Conclusions
Through the sharing at European level of a standardized
collection of evidences obtained with these instruments,
it would be possible to collect a large and robust amount
of clinical evidences to be used for clinical research
development.
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